During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...

Accelerated approval targets R/R MCL after prior BTK inhibition, addressing an area of high unmet need with limited established salvage standards. Phase 1/2 data at 320 mg QD showed ORR 52.4% and CR ...

Dr. Leal addresses diagnostic challenges with newer therapies, particularly tarlatamab's potential neurologic side effects ...

Dr. Leal introduces amifampridine, an FDA-approved oral potassium channel blocker that increases acetylcholine release at ...

Andrzej Jakubowiak, MD, PhD, director of the multiple myeloma program at the University of Chicago, discusses the definitive results of the phase 3 ATLAS trial (NCT02659293), recently published in The ...

Clinical care remains anchored in disease-specific expertise, but is augmented by wraparound services tailored to life stage.

RAINIER is a multicenter, open-label, multi-cohort phase 1b/2 dose-optimization study enrolling adults aged 18 years or older ...

Dr. Leal discusses the updated NCCN guidelines recommending VGCC antibody testing for patients with suspected neurologic ...

Dr. Ticiana Leal from Emory University's Winship Cancer Institute and Dr. Wade Iams from Tennessee Oncology introduce their ...

First-line treatment selection in HER2-mutant NSCLC balances route of administration, efficacy data by mutation subtype, and ...

Response outcomes compared favorably with historical single-agent pembrolizumab activity in recurrent ovarian cancer (KEYNOTE ...